Status:
UNKNOWN
Ranolazine Loading to Prevent PCI-induced Myocardial Injury
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
It has previously been shown that pretreatment with ranolazine 1,000 mg twice daily for 7 days can significantly reduce procedural myocardial injury in elective percutaneous coronary intervention (PCI...
Detailed Description
Background Ranolazine is a novel antianginal drug that reduces intracellular sodium and calcium accumulation during ischemia thus limiting ischemic injury. It has previously been shown that pretreat...
Eligibility Criteria
Inclusion
- Angiographically-proven coronary artery disease
- Class I indication to elective percutaneous coronary intervention
- Stable conditions
- No recent acute coronary syndromes
- Normal baseline values of markers of myocardial damage (creatine kinase, creatine kinase-MB, myoglobin, and troponin I)
- Able to understand and willing to sign the informed consent form
Exclusion
- • Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01491061
Start Date
January 1 2014
End Date
December 1 2017
Last Update
March 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Raffaele Pisana
Rome, Italy, 00100